VivoSeq
Oncology

Prostatic Neoplasms

29

Pipeline Programs↗

20

Active Trials↗

9

Companies Involved↗

Prostatic Neoplasms is an emerging landscape with 29 programs across 9 companies. The most active players are Bayer, Purdue Pharma LP, Glaxo Dba Glaxosmithkline. 16 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

40/100

Completion Rate

60/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1P

Purdue Pharma LP

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Astellas logo

Astellas

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

20 of 22 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody15%Radiopharmaceutical15%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 75% of 32 pipeline programs.

Analysis

Trial Status

25

clinical trials

Active, not recruiting12 · 48%
Recruiting8 · 32%
Completed3 · 12%
Terminated2 · 8%

Clinical Trials

Trial Activity

25 trials

A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05616650·42 enrolled
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Recruiting·National Cancer Institute (NCI)·N/A·NCT03805919·500 enrolled
Double-DARE: Analysis of Doublet and Triplet Therapy With Darolutamide and Other Androgen Receptor Pathway Inhibitors in de Novo mHSPC Patients Seen in Urology Clinics in the USA
Recruiting·Bayer logoBayer·N/A·NCT07406282·1,400 enrolled
An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07451002·540 enrolled
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT07082920·140 enrolled
A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT07319871·40 enrolled
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06095089·355 enrolled
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Recruiting·National Cancer Institute (NCI)·N/A·NCT01834001·300 enrolled
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT04689828·469 enrolled
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04557059·692 enrolled
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT04898634·216 enrolled
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT02257736·982 enrolled
A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT04644770·144 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT01946204·1,207 enrolled
An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT04577833·136 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)